Grupo para la caracterización molecular de las neoplasias hematológicas
Instituto de Investigación Sanitaria La Fe
Valencia, EspañaPublications en collaboration avec des chercheurs de Instituto de Investigación Sanitaria La Fe (19)
2023
-
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
Blood Cancer Journal, Vol. 13, Núm. 1
-
Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry
Cancers, Vol. 15, Núm. 2
2022
-
Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 27, pp. 3151-3161
-
Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study
Cancers, Vol. 14, Núm. 23
-
No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group
Disease markers, Vol. 2022, pp. 3132941
2021
-
A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients
Annals of Hematology, Vol. 100, Núm. 6, pp. 1497-1508
-
Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)
PLoS ONE, Vol. 16, Núm. 9 September
-
NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma
Blood Cancer Journal, Vol. 11, Núm. 8
-
Polycythemia vera and essential thrombocythemia patients exhibit unique serum metabolic profiles compared to healthy individuals and secondary thrombocytosis patients
Cancers, Vol. 13, Núm. 3, pp. 1-12
-
Reference values to assess hemodilution and warn of potential false-negative minimal residual disease results in myeloma
Cancers, Vol. 13, Núm. 19
2020
-
Analysis of SNP Array Abnormalities in Patients with DE NOVO Acute Myeloid Leukemia with Normal Karyotype
Scientific Reports, Vol. 10, Núm. 1
-
Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis
Medicina Clinica, Vol. 155, Núm. 4, pp. 152-158
-
Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project
Haematologica, Vol. Online ahead of print
2019
-
Immediate effects of dasatinib on the migration and redistribution of naïve and memory lymphocytes associated with lymphocytosis in chronic myeloid leukemia patients
Frontiers in Pharmacology, Vol. 10
-
Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial
Digestive and Liver Disease, Vol. 51, Núm. 4, pp. 529-535
2018
-
Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia
British Journal of Haematology
-
Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia
Journal of Hematology and Oncology, Vol. 11, Núm. 1
-
Prognostic risk models for transplant decision-making in myelofibrosis
Annals of Hematology, Vol. 97, Núm. 5, pp. 813-820
2017
-
Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis
European Journal of Haematology, Vol. 98, Núm. 4, pp. 407-414